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Abstract
Introduction Mucin 1 (MUC1) is a high molecular weight
glycoprotein overexpressed on adenocarcinoma cells and is a
target for immunotherapy protocols. To date, clinical trials
against MUC1 have included advanced cancer patients. Herein,
we report a trial using early stage breast cancer patients and
injection of oxidized mannan-MUC1.
Method In a randomized, double-blind study, 31 patients with
stage II breast cancer and with no evidence of disease received
subcutaneous injections of either placebo or oxidized mannan-
MUC1, to immunize against MUC1 and prevent cancer
reoccurrence/metastases. Twenty-eight patients received the
full course of injections of either oxidized mannan-MUC1 or
placebo. Survival and immunological assays were assessed.
Results After more than 5.5 years had elapsed since the last
patient began treatment (8.5 years from the start of treatment of
the first patient), the recurrence rate in patients receiving the
placebo was 27% (4/15; the expected rate of recurrence in
stage II breast cancer); those receiving immunotherapy had no
recurrences (0/16), and this finding was statistically significant
(P = 0.0292). Of the patients receiving oxidized mannan-MUC1,
nine out of 13 had measurable antibodies to MUC1 and four out
of 10 had MUC1-specific T cell responses; none of the placebo-
treated patients exhibited an immune response to MUC1.
Conclusion The results suggest that, in early breast cancer,
MUC1 immunotherapy is beneficial, and that a larger phase III
study should be undertaken.
Introduction
Outcomes of breast cancer treatment have improved, mostly
as a result of earlier diagnosis. Although newer modes of ther-
apy are being applied, traditional therapy involving surgery,
radiotherapy and chemotherapy, followed by long-term
antioestrogen therapy continues to be used. Immunotherapy
could be a useful adjunct to conventional therapy, particularly
in an adjuvant setting and (as shown here) in patients with
early disease and no metastasis. New therapeutic procedures
in breast cancer are usually tried in patients with advanced dis-
ease, who may be appropriate candidates for cytotoxic drugs.
However, such patients may be unable to respond appropri-
ately to immunotherapy, given that an intact and competent
immune system is required to induce a therapeutic immune
response.
Treatment of cancer with immunotherapy has been the goal of
many researchers since the advent of effective immunization
against infectious diseases. Previously, tumour antigens were
not easily identified, but currently identified antigens include
glycoproteins and glycolipids (for example, gangliosides),
developmental and over-expressed antigens (for example,
CEA (carcinoembryonic antigen), gp75, MAGE, tyrosinase,
melan-A, mucin [MUC]1), and mutated oncogenes (for exam-
ple, p53, HER-2/neu, ras) [1]. Our laboratory has focused on
MUC1 as a target for tumour immunotherapy. Mucins (such asPage 1 of 11
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secreted by many epithelial cells such as breast, ovary, colon
and pancreatic carcinomas. MUC1 is of interest and a poten-
tial target for tumour immunotherapy for the following reasons:
there is an up to 100-fold increase in the amount of mucin
present on cancer cells compared with normal cells; MUC1
has a ubiquitous rather than focal cellular distribution; and
MUC1 has altered glycosylation, revealing peptide epitopes
not easily identified in normal mucins.
Cloning of the cDNA for MUC1 and definition of the structure
revealed that the molecule is transmembranous, with a rela-
tively large extracellular domain and a cytoplasmic tail. It was
discovered that most of the immunogenicity (in terms of anti-
body production) resided in a repeated (variable number of
tandem repeats [VNTR]) 20-amino-acid peptide (PDTRPAPG-
STAPPAHGVTSA) domain in the extracellular portion of the
molecule [2-4]. Such studies of immunogenicity in mice would
not be relevant to humans other than the findings that, in
humans, MUC1 can stimulate T cells in breast, pancreatic and
ovarian cancers [5-7]. Restricted cytotoxic T lymphocytes in
humans with breast cancer and in pregnancy, as well as in
mice, have also been detected [8-10]. In addition, T cell immu-
nity and B cell immune responses to selected epitopes of
MUC1 from ovarian, breast, pancreatic and colon cancer
patients have been demonstrated [11-13], as have circulating
immune complexes to MUC1 in the serum of breast and ovar-
ian carcinoma patients [14]. In mice, we demonstrated that a
20-mer MUC1 VNTR (made as a fusion protein comprising
five VNTR repeats), when coupled to oxidized mannan (that is,
oxidized mannan-MUC1 fusion protein [M-FP]), generates H2
restricted cytotoxic T lymphocytes, which protect mice against
challenge with MUC1+ mouse tumours [9,15-22].
Over the past 12 years, we have injected many patients with
different MUC1 formulations in an effort to induce protective
and therapeutic immunity, aiming to reproduce the same effect
as seen in mice [1,9,16-20,23-35]. In more than 250 patients
with advanced cancer, moderate cellular immune responses
and substantial antibody responses were noted [36-39]. How-
ever, clinical responses were not apparent in these patients,
possibly because of the advanced and immunocompromised
state of their disease. Therefore, in the present study we aimed
to evaluate the effect of M-FP in patients with early disease.
Specifically, these patients had stage II disease with fewer
than four lymph nodes involved, all of which had been
removed, and had no evidence of disease and were entirely
healthy at the start of the trial. Although a small number of
patients were recruited into this randomized, double-blind pilot
study, the early results reported here are promising and justify
the performance of a larger study.
Materials and methods
Patient recruitment
A total of 31 postmenopausal women with stage II breast can-
cer (oestrogen receptor positive and with involvement of no
more than four ipsilateral nodes) and no evidence of distant
disease participated in the study. All patients received
tamoxifen. The patients were selected and treated at Prolipsis
Medical Center, Athens, Greece. The study was initiated once
ethics approval had been granted by the National Drug Admin-
istration, Greece (EOF) (26 September 1997, no. 27581).
The inclusion and exclusion criteria are summarized in Table 1.
Staging of the disease was done by conventional measure-
ments, chest radiography, bone scan, and ultrasonography of
upper and lower abdomen (to rule out distant metastases).
The age of the patients was 51–81 years (mean 59.5 years).
The histologic type of the tumor in 28 patients was infiltrating
adenocarcinoma. The grading was as follows: grade I in six
cases, grade II in 19 cases, and grade III in three cases. In
three patients the histologic type was infiltrating lobular carci-
noma with no grading. All tumours were positive for oestrogen
receptor. The size of the primary tumour ranged from 0.5 to 3.2
cm (mean 1.8 cm). The total number of excised lymph nodes
per patient ranged from eight to 29 (mean 18.3). The positive
nodes per patient ranged from one to four (mean 1.7) (Table
1).
Preparation of MUC1 fusion protein, pVNTR and 
conjugation to oxidized mannan
The MUC1 fusion protein (FP), consisting of glutathione-S-
transferase (GST; 26 kDa) and three MUC1 VNTR repeats
(PDTRPAPGSTAPPAHGVTSA) plus two flanking homolo-
gous sequences (12 kDa), was induced in Escherichia coli
and purified (as described previously) [40]. Mannan (Sigma,
St. Louis, MO, USA) was oxidized and conjugated to FP to
form M-FP (oxidized mannan-FP; as described previously)
[19,20,36,38]. An alternative source of the antigen, not con-
taining GST, was prepared to assay VNTR-specific immune
responses in ELISpot and ELISA assays. pVNTR recombinant
protein was expressed in E. coli using the pTrcHisB vector
(Invitrogen, Carlsbad, CA, USA) containing the pDF9.3 insert
and purified on a Nickel-NTA column (Qiagen, Melbourne,
VIC, Australia). pVNTR contains the same MUC1 sequence as
FP (above) but with no GST and His6 for purification. M-FP
and pVNTR were tested for sterility (presence of bacteria and
fungi; Austin Health, Department of Medical Microbiology,
Heidelberg, VIC, Australia) and bacterial endotoxin activity
(EML Group of Laboratories, Melbourne, VIC, Australia). The
MUC1 was conjugated to oxidized mannan (to target the man-
nose receptor) [16,24] using periodate; this leads to the for-
mation of aldehydes, which are critical for rapid exit from
endosomes and entry into the major histocompatibility com-
plex class I pathway [18]. Placebo consisted of the conjuga-
tion buffer (bicarbonate buffer; pH 9.0) alone. The vaccine was
prepared under Good Laboratory Practice (GLP) guidelines atPage 2 of 11
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toxin levels were above 0.06 and below 0.6 EU/ml. M-FP vac-
cine was also tested for activity using ELISA binding assays
and by sodium dodecyl sulphate gels. The vials were number
coded by randomization and sent to Prolipsis Medical Center
(Athens, Greece) from the Burnet Institute, and stored at -
20°C; the codes were held by Burnet Institute.
Immunotherapy schedule, blood samples and 
assessment of clinical status
Commencing 3 months after surgery, 31 patients with early-
stage breast cancer were given seven injections at 2-week
intervals of M-FP or placebo for the first 12 weeks and then at
6 and 9 months (Table 2). Blood samples were taken before
and at intervals after M-FP or placebo injections. Peripheral
blood mononuclear cells (PBMCs) were isolated from
heparinized blood by centrifugation with Ficoll-Paque and
stored in liquid nitrogen at the National Hellenic Foundation
until they were sent in dry ice to the Burnet Institute for immu-
nological analysis (antivaccine IFN-γ T cell immunity). Serum
samples were also collected from patients and stored at -20°C
to monitor antibody responses (Table 2). Follow-up tests
included laboratory tests at Prolipsis Medical Center, chest
radiographs, and upper and lower abdominal ultrasound every
three months for five years. Bone scans and mammography
were performed every year for up to 7 years/10 months (Table
2). Patients' breast tumours were not assessed for MUC1
expression in this trial; however, we have found that more than
90% of breast cancers express MUC1, and so it is likely that
most of the patients were positive for MUC1 expression [3,4].
We have tested for MUC1 expression in dendritic cell/M-FP
injected patients [41], and in the trial currently in progress.
Table 1
Inclusion and exclusion criteria for participation in the study
Criteria Details
Inclusion Postmenopausal women (no menstrual period for >12 months)
Histological proven adenocarcinoma of the breast treated primarily by modified radical or 
partial mastectomy and axillary dissection followed by radiotherapy of the residual breast
No more than four ipsilateral lymph nodes with metastases, not extending into the surrounding 
tissue and surgical margin free from disease
Tumor tissue positive for oestrogen receptor
Tamoxifen 20 mg/day commencing within 3 months of breast surgery and to continue for 5 
years (provided by A. Dervos – G Dimitrakopoulos &Co OE)
Adequate bone marrow function (white blood cell count >4.0 × 109/l, haemogoblin >100 g/l, 
platelet count >100 × 109/l)
Adequate liver function (billirubin <60 µmol/l [that is, under three times the upper limit of 
normal)
Adequate renal function (creatinine <140 µmol/l)
Life expectancy >12 weeks
ECOG (Eastern Cooperative Oncology Group) status between 0 and 2 (In bed <50% of 
daytime)
Written informed consent by the patient.
Exclusion criteria Known metastatic breast cancer
Radiotherapy, chemotherapy, immunotherapy, or investigation therapy within the preceding 
four weeks
Previous splenectomy or radiotherapy to spleen
Coexisting or previous other malignancies except in situ carcinoma of the cervix or basal cell 
carcinoma of the skin
Active uncontrolled infection
Psychiatric, addictive, or any disorder that compromises ability to give truly informed consent 
for participation in or to comply with the requirements of the study
Concurrent systematic corticosteroid treatment
Autoimmune disease (that is, rheumatoid arthritis, systematic lupus erythematosus; except 
autoimmune thyroiditis)Page 3 of 11
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Vaccination (with M-FP or placebo), testing and follow up
Day Weeks Months Every 3 
Months
1 year Every 
year
1 2 4 6 8 10 12 4 5 6 7 8 9
Staging of the 
disease
+
Vaccine + + + + + + + + +
T cell test +a +b +c +d +e +f +g, h
Antibody test +a +b +c +d +e +f +g, h
Clinical 
examination
+ + + + + +
Follow-up tests + + + +
Bone scan and 
mammography
+ +
For T cell tests and antibody tests sample numbers are highlighted within the box as superscript, indicating time points at which immunological tests 
were carried out: afirst injection; bweek 6 (2 weeks after the third injection); cweek 12 (2 weeks after the sixth injection); d6 months (3 months after 
the seventh injection); e9 months (3 months after the eighth) injection; f1 year (3 months after the final [ninth] injection); g2 years (1 year and 3 
months after the final injection); h3 years (2 years and 3 months after the final injection). Day 1 is the day of first vaccination. Follow up was every 3 
months for 5 years. Antibody test = blood for testing antibody levels; Follow-up tests = laboratory tests, chest X-ray, upper and lower abdominal 
ultrasound; M-FP, oxidized mannan conjugated to MUC1 fusion protein; T cell test = PBMC for testing IFN-γ; Vaccine = M-FP or placebo 
administered subcutaneously.
Table 3







Type of treatment Tumour size 
(cm)
Total nodes Metastatic 
nodes
Grade Date of first 
injection




1 58 02/12/97 Partial mast + RT + tam 1.0 17 1 II 21/01/98 Mild skin 
redness
- 13/06/05 90
2 72 14/01/98 Total mast + tam 2.0 12 1 I 03/02/98 Mild skin 
redness
- 13/06/05 89
3 52 24/03/98 Partial mast + RT + tam 1.3 20 2 II 16/11/98 - - 13/06/05 87
4 53 22/05/98 Partial mast + RT + tam 1.5 23 2 III 30/11/98 - - 15/06/05 85
5 53 03/09/98 Total mast + tam 3.0 21 4 a 23/09/98 - - 15/06/05 81
6 58 10/11/98 Total mast + tam 1.5 22 3 II 30/11/98 Mild skin 
redness
- 15/06/05 79
7 78 08/12/98 Bilateral total mast +tam Right 1.2 
Left 1.2
18 16 0 4 I I 28/12/98 - - 17/06/05 78
8 62 27/01/99 Partial mast + RT + tam 1.0 8 1 II 16/02/99 Mild skin 
redness
- 17/06/05 77
9 61 01/04/99 Partial mast + RT + tam 2.0 18 1 I 26/04/99 - - 17/06/05 74
10 58 21/04/99 Partial mast + RT + tam 2.0 17 3 II 07/05/99 - - 20/06/05 74
11 53 13/07/99 Partial mast + RT + tam 2.3 29 1 a 19/08/99 Mild skin 
redness
- 20/06/05 71
12 59 16/09/99 Total mast + tam 1.4 19 1 I 26/06/00 - - 20/06/05 69
13 59 10/11/99 Total mast + tam 0.7 10 1 a 22/11/99 - 22/06/05 67
14 63 09/02/00 Partial mast + RT + tam 1.2 13 1 II 01/03/00 - - 22/06/05 64
15 55 10/02/00 Partial mast + RT + tam 2.5 23 3 II 25/02/00 - - 24/06/05 64
16 65 29/06/00 Partial mast + RT + tam 0.8 17 1 II 17/07/00 Mild skin 
redness
- 24/06/05 60
aThe histologic type was invasive lobular adenocarcinoma with no grading. mast, mastectomy; M-FP, oxidized mannan conjugated to MUC1 fusion 
protein; RT, radiotherapy; tam, tamoxifen.Page 4 of 11
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ELISpot cytokine assays (measurement of IFN-γ secretion 
by T cells)
Plates (96-well, MAIPS S45; Millipore, Sydney, Australia)
were precoated with 50 µl anti-human IFN-γ antibody (1D1K;
Mabtech, Meblbourne, Australia). Triplicate wells were set up
for each condition. Each test well contained 0.5 × 106 viable
thawed PBMCs in 100 µl RPMI-1640 medium supplemented
with glutamine, penicillin, streptomycin and 2.5% (vol/vol)
human AB serum (Valley Biomedical, Winchester, VA, USA),
plus 25 µl control additive or antigen (purified protein deriva-
tive (PPD; Tuberculin, Staten Serum Institute, Copenhagen,
Denmark; positive control antigen), recombinant pVNTR (spe-
cific test antigen), or no antigen (negative control]) to a final
concentration of 20 µg/ml. The plates were incubated for 18
hours at 37°C in 5% carbon dioxide. The cells were removed
with sequential washes of phosphate-buffered saline (PBS)
containing 0.1% vol/vol Tween 20 then PBS, and the plates
were incubated with biotin-conjugated anti-human IFN-γ anti-
body (7-B6-1; Mabtech) for 2 hours at room temperature
before washing. Bound cytokine was visualized using 1 µg/ml
streptavidin-alkaline phosphatase conjugate (Mabtech) incu-
bated for 2 hours at room temperature, and then incubation
with the colorimetric AP detection kit in accordance with the
manufacturer's instructions (BioRad, Salt Lake City, UT, USA).
Cytokine spots were counted using the AID ELISpot Reader
system (Autoimmun Diagnostika GmbH, Strassberg, Ger-
many). PPD was used as a positive control antigen that all
patients were expected to respond to, particularly to validate
PBMC sample viability and reactivity.
ELISA assays (measurement of IgM and IgG antibody 
levels)
Anti-MUC1 VNTR antibodies were measured using ELISA
against pVNTR recombinant protein. ELISA plates (Costar,
Temecula, CA, USA) were coated with 50 µl of a 5 µg/ml anti-
gen solution in 0.05 mol/l sodium carbonate buffer (pH 9.6) for
2 hours at 37°C. Plates were washed five times in 0.1% vol/
vol Tween 20 in PBS and then in PBS, and were blocked with
2.5% vol/vol human AB serum in PBS (100 µl) for 1 hour at
37°C. The plates were washed and test sera, diluted 1/40 in
1% vol/vol human AB serum-PBS, were added and incubated
for 2 hours at 37°C. Following five washes with 0.1% (vol/vol)
Tween 20 in PBS and five washes with PBS, bound serum
antibodies were visualized with 50 µl of isotype and class-spe-
cific sheep anti-human immunoglobulin, anti-IgG, or anti-IgM
antisera, each labelled with horseradish peroxidase (Silenus
Laboratories, Hawthorn, Australia) and diluted to 1:500 in 1%
(vol/vol) AB serum and incubated for 1 hour at 37°C. The
plates were washed and developed with 0.03% vol/vol 2,2-
azino-di-(3-ethylbenzthiozoline sulfonate) in 0.1 mol/l citrate
buffer (pH 4.0). Absorbance was measured at 405 nm using
an ELISA plate reader (FLUOstar Optima plate reader; BMG
Labtechnologies GmbH, Offenberg, Germany). A positive
control serum was selected from a panel, being from a patient
previously immunized with M-FP (IFCM10_#2EC) who had
developed an anti-VNTR IgM and IgG antibody response. The
negative control serum was selected from a panel, being from
a normal individual (ARI_#S2P) with no detectable anti-VNTR
antibody. The antibody reactions are presented as percentage
positive of test sera compared with positive control sera, after
validating that there was no nonspecific antibody binding of
test or control sera (diluted 1/40) to empty wells and the neg-
ative control reaction was under 15% compared with the pos-
itive serum.
Statistical analysis of protective efficacy against relapse
The data for the placebo and M-FP group was plotted as Kap-
lan-Meier survival curves using the PRISM program [42].
Results
Clinical findings and patient characteristics
The first patient was injected on 13 December 1997 and the
last patient on 17 July 2000. On 18 June 2003 the vaccine
code was broken, identifying the 16 patients who had been
injected with M-FP (Table 3) and the 15 who had been
injected with placebo (Table 4). Of the M-FP injected patients
none of 16 had relapse of disease and four out of 15 placebo
patients had recurrent disease. Three out of 31 patients did
not complete the injection programme, all of whom were in the
placebo group; one patient refused to continue in the pro-
gramme after the eighth injection and developed local metas-
tases 2 months later (Table 4). The second patient stopped
the treatment after three injections and the third patient after
the first injection. The follow-up period ranged from 60 to 99
months. As of May 2006 there have been no changes to the
clinical findings reported here.
The characteristics of the patients in the M-FP vaccinated
group, and their pathology and follow up are presented in
Table 3. As noted in Table 3, the age of the patients ranged
from 52 to 78 years (mean 59.9 years). Modified radical mas-
tectomy was performed on six patients and partial mastectomy
with radiation on 10 patients. The histological type of the
tumour was infiltrating adenocarcinoma. In three cases the his-
tological type was infiltrating lobular carcinoma. The grading
was I in four patients, II in eight and III in one. In the three cases
of lobular carcinoma we had no grading data. Tumour size
ranged from 0.8 to 3 cm (mean 1.5 cm). The total number of
excised lymph nodes per patient ranged from eight to 29
(mean 17.9). The number of positive nodes per patient ranged
from one to four (mean 1.8). Mild skin redness was noticed in
six patients at the area of vaccination and needed no treat-
ment. The follow up of these patients ranged from 60 to 90
months (mean 75.6 months) and no signs of recurrence were
evident.
The characteristics of the patients in the placebo group, and
their pathology and follow up are presented in Table 4. The
age of the patients ranged from 51 to 81 years (mean 68.8Page 5 of 11
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patients and partial mastectomy, axillary dissection and radia-
tion in nine patients. Tumour size ranged from 1.5 to 3.2 cm
(mean 2.1 cm). The histological type of the tumor in all 15
patients was infiltrating adenocarcinoma. The grading was I in
one patient, II in 12 patients and III in two patients. The total
number of dissected lymph nodes per patient was 11 to 27
(mean 18.9). The number of positive nodes per patient ranged
from one to three (mean 1.6). Mild skin redness was noticed in
four patients and needed no treatment. Four patients from this
group presented with metastatic disease. One patient devel-
oped liver metastases 9 months after surgery and died 1.5
years later. A second patient developed bone metastases 24
months after surgery and died 3 years later. Two other patients
developed bone and local metastases 18 and 19 months after
surgery and they are still living with disease 76 and 90 months
after surgery. The remaining 11 patients, with follow up rang-
ing from 75 to 99 months (mean 91.0 months), are living free
from disease. Inspection of characteristics between the two
groups indicates that they are appropriate for statistical
comparison.
ELISpot assays of IFN-γ secretion by T cells
Because of cell storage problems and transport of frozen cells
from Greece to Melbourne, only 63% (10/16) and 53% (8/15)
of samples in the vaccinated and placebo groups exhibited
viability in excess of 80% upon recovery and were tested by
ELISpot. The cells that were viable were functionally active
because they responded to PPD (Figure 1) and all these sam-
ples were validated by proliferative response to Phytohemag-
glutinin (data not shown) before they were evaluated using the
assays. IFN-γ secreting T cells were generated in 40% (4/10)
of samples from patients immunized with M-FP (patient num-
bers 3, 5, 11 and 14; Table 3). T cells were shown to be spe-
cific for MUC1 VNTR (pVNTR). Examples of responses in
patients (3, 5, 11 and 14) receiving M-FP are shown in Figure
1. Patient 14 exhibited no IFN-γ T cell responses to pVNTR in
samples 1, 2 and 3 but significant responses in samples 4 and
5 (sample numbers shown in Table 2; Figure 1). Patient 5 had
high IFN-γ T cell responses to pVNTR in samples 6, 7 and 8
but, because of to low cell viability, we were unable to test
samples 1–5 (Figure 1). Likewise, for patient number 3, only
samples 7 and 8 are shown. Sample 6 corresponds to 1 year
after the first injection, and samples 7 and 8 correspond to
blood taken after 2 and 3 years, respectively. Thus, in patient
5 T cell responses were detectable up to 2 years after the first
injection, and in patient 3 they were detectable 3 years after
the first injection. We tested pVNTR responses in more 20
nonimmunized individuals and all exhibited no responses to
pVNTR (data not shown). Thus, it is probable that the
responses to pVNTR would be negative in sample 1 (taken on
the day of vaccine injection) from patients 3 and 5. Patient
number 11 had detectable pVNTR IFN-γ responses in sam-
ples 2, 3 and 4. Of the eight samples tested from the placebo
Table 4







Type of treatment Tumour size 
(cm)
Total nodes Metastatic 
nodes
Grade Date of first 
injection




17 62 11/12/97 Total mast + tam 2.5 27 1 II 28/01/98 Mild skin 
redness
- 14/06/05 99
18 54 14/12/97 Partial mast + RT + tam 2.0 20 1 II 10/01/98 - Local, 14/07/99 14/06/05 99
19 55 16/12/97 Partial mast + RT + tam 1.5 17 1 II 06/05/98 - - 14/06/05 99
20 60 23/12/97 Partial mast + RT + tam 2.3 24 2 II 13/12/97 - - 16/06/05 99
21 62 20/01/98 Total mast + tam 2.4 27 2 II 13/03/98 - - 16/06/05 98
22 61 13/03/98 Total mast + tam 1.8 23 2 I 29/04/98 - - 17/06/05 97
23 62 01/04/98 Partial mast + RT + tam 1.5 12 1 II 08/07/98 Mild skin 
redness
- 17/06/05 96
24 54 29/04/98 Partial mast + RT + tam 0.5 17 1 III 22/07/98 Mild skin 
redness
- 21/06/05 96
25 58 10/11/98 Total mast + tam 2.2 21 3 II 30/01/98 - Bone, 13/11/00 Death 10/
11/03
26 51 17/02/99 Partial mast + RT + tam 2.0 11 1 II 10/03/99 - Bone, 28/09/00 21/06/05 86
27 71 10/06/99 Total mast + tam 3.2 26 1 II 01/07/99 - - 23/06/05 82
28 70 30/06/99 Partial mast + RT + tam 2.0 20 3 II 13/07/99 - - 23/06/05 82
29 54 02/12/99 Partial mast + RT + tam 2.5 12 1 II 10/01/00 - - 24/06/05 76
30 81 08/12/99 Total mast + tam 2.5 14 1 III 10/01/00 - - 27/06/05 75
31 58 24/02/00 Partial mast + RT + tam 2.0 13 3 II 20/03/00 Mild skin 
redness
Liver, 16/11/00 Death 2002
mast, mastectomy; M-FP, oxidized mannan conjugated to MUC1 fusion protein; RT, radiotherapy; tam, tamoxifen.Page 6 of 11
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ble (data not shown). Furthermore, we did not detect IFN-γ
responses by ELISpot among patients receiving placebo or in
pretreatment samples (for example, sample 1; Figure 1). The
ELISpot results are statistically significant (P < 0.05) for the
comparison with sample number 1 in patients 11 and 14, and
for the comparison with negative control in all patients.
Measurement of antibodies by ELISA assays
Anti-VNTR serum antibodies were induced in nine out of 13
participants who had received M-FP. These were initially IgM,
and seroconverted to IgG and persisted up to 12–24 months
after immunization. Representative antibody reactions from
seven patients (patients 3, 4, 5, 7, 8, 10 and 11) are shown in
Figure 2. Sample 1 denotes the pretreatment sample from
each patient. Thus, antibodies were detected only after vacci-
nation. No detectable antibody levels were found in the
patients receiving placebo in all samples tested (not shown).
We did not detect antibodies to MUC1 in the placebo group
or in the pretreatment samples of M-FP immunized patients
(sample 1; Figure 2). However, we note that background IgM
levels in sample 1 were higher in patient 3, which increased
threefold after injections with M-FP compared with all other
patients' samples. The antibody results are statistically signifi-
cant (P < 0.05) for the comparison with sample 1 in each
patient group.
Statistical analysis of protective efficacy against relapse
The data for the placebo and M-FP group were plotted as Kap-
lan-Meier survival curves using the PRISM program [42]. All
patients enrolled in the trial were assessed and included the
patients who did not receive the complete treatment. All of the
patients with relapses and no relapses were analysed, with
time of observation ranging from 60 to 99 months. The vertical
bars are the last day of follow up. The placebo and M-FP
curves were compared using the log rank test and found to dif-
fer significantly (P = 0.0292 and χ2 4.812; Figure 3).
Discussion
In this long-term, double-blind study of 31 individuals with
stage II breast cancer and no evidence of disease (16 injected
with M-FP and 15 with placebo), patients receiving M-FP vac-
cination appeared to benefit in terms of protection against
relapse; none of 16 had a recurrence, but four out of 15 pla-
Figure 1
IFN-γ secreting T cells in patients immunized with M-FP. Patient numbers 14, 5, 3 and 11 are shown. Responses to VNTR (pVNTR (which contains 
five VNTR repeats with no GST); black), PPD (internal positive control; grey) and no antigen (negative control; white). 1 = first injection; 2 = week 6 
(2 weeks after the third injection); 3 = week 12 (2 weeks after the sixth injection); 4 = 6 months (3 months after the seventh injection); 5 = 9 months 
(3 months after the eighth injection); 6 = 1 year (3 months after the final (ninth) injection); 7 = 2 years, and 1 year and 3 months after the final injec-
tion; 8 = 3 years, and 2 years and 3 months after the final injection. GST, glutathione-S-transferase; IFN, interferon; M-FP, oxidized mannan conju-
gated to MUC1 fusion protein; PPD, purified protein derivative; SFU, spot forming units; VNTR, variable number of tandem repeats (from MUC1 
sequence).Page 7 of 11
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months (December 1997 to October 2005). Although the
number of patients in this study is small, the results are statis-
tically significant (P = 0.0292). Most of the treated patients
exhibited immunity to MUC1 VNTR, whereas none of the pla-
cebo patients had such immune responses. Thus, M-FP
appears to confer the survival/disease-free interval advantage
in patients with early breast cancer. Importantly, and in con-
trast to other studies, the findings presented here for vaccina-
tion of patients with early disease provide justification for
performance of a larger study. Indeed, a strategy of using a
small number of patients to obtain an indication of response
would be worth considering for immunotherapy trials, in which
virtually all patients should exhibit an immune response if the
therapy is working, and a high proportion of those should
exhibit an anti-tumor response; this contrasts with cancer
chemotherapy, in which fewer patients are likely to respond.
The study is of interest for several reasons. First, we highlight
the characteristics of the patients evaluated in the present
study; these patients had early disease, they presented with a
primary lesion, they had lymph nodes surgically removed, and
at the time of commencement of the trial they had no evidence
of disease. We consider these characteristics to be crucial if
immunotherapeutic studies are to yield useful findings. In
another trial [43], a potentially therapeutic monoclonal anti-
body (CO17-1A) was used in 83 patients with minimal resid-
ual colorectal cancer (Dukes C) after surgery, and some
patients remained tumour free for many years. Furthermore, in
a placebo-controlled clinical trial using NY-ESO-1 protein
(cancer testis protein) with ISCOMATRIX adjuvant in early-
stage melanoma patients [44], immunized patients exhibiting
antibody, delayed-type hypersensitivity, and CD4+ and CD8+
T cell responses appeared to have superior clinical outcomes
to those treated with placebo or protein alone. Unfortunately,
most cancer trials involve patients with advanced disease,
selected on the basis of traditional therapy involving toxic
chemotherapeutic agents. However, such patients are likely to
have poor immune responses, significant tumour bulk, limited
time for the induction and effector phases of specific immunity,
and are the least likely to have therapeutic benefit from immu-
notherapy regimens. We do not advocate abandonment of the
traditional approach of phase I studies, in which the primary
end-point is assessment of toxicity, but we do recommend that
these pilot studies of immunotherapeutic agents be quickly fol-
lowed by larger studies in patients with early disease. In our
experience to date, more than 250 other patients have
received M-FP by direct injection but all had advanced dis-
ease; no toxic effects were detected but – importantly – none
had objective clinical responses [36-39]. We hope that the
present study will encourage use of immunotherapy in patients
with early disease, but we note the long follow-up time
required (and the large number of patients) if meaningful
results are to be to obtained.
Figure 2
Antibody (IgM and IgG) responses to VNTR in patients immunized with M-FP. Representative examples from patients 3, 4, 5, 7, 8, 10 and 11. 1 = 
first injection; 2 = week 6 (2 weeks after the third injection); 3 = week 12 (2 weeks after the sixth injection); 4 = 6 months (3 months after the sev-
enth injection); 6 = 1 year and 3 months after the final (ninth) injection; 7 = 2 years, and 1 year and 3 months after the final injection. A positive con-
trol serum was selected from a panel, being from a patient previously immunized with M-FP (IFCM10_#2EC) who had developed an anti-VNTR 
antibody response. Negative control serum was selected from a panel, being from a normal individual (ARI_#S2P) with no detectable anti-VNTR 
antibody. The antibody reactions are presented as percentage positive of test sera compared with positive control sera (where the negative control 
serum reaction was <15% of positive serum). M-FP, oxidized mannan conjugated to MUC1 fusion protein; VNTR, variable number of tandem repeats 
(from MUC1 sequence).Page 8 of 11
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of the patients had a cellular immune response (of the samples
that could be tested), and most had a significant antibody
response. In contrast to patients from other clinical trials of M-
FP [36-39,41], we did not detect IFN-γ, cytotoxic T lym-
phocytes, or proliferation of T cells to pVNTR in pretreatment
samples. Interestingly, pre-existing peptide-reactive T cell
responses (IFN-γ) to MUC1, as measured using quantitative
polymerase chain reaction, have been detected in normal
donors and in patients with primary breast cancers [45]. How-
ever, the responses were against different MUC1 antigens,
namely short peptide epitopes MUC1950–958 (STAPPVHNV)
and MUC112–20 (LLLLTVLTV), which are outside the MUC1
VNTR region and were not incorporated in our M-FP vaccine.
We did not detect anti-MUC1 antibody levels in pretreatment
samples in other M-FP clinical trials either [36-39,41].
Although our finding is contradictory to those of previous stud-
ies [11,12,46], this is possibly due to differences in ELISA
methodology or the antigen used to coat the ELISA plates
(recombinant pVNTR in our studies versus peptide in other
studies), which would mean that the conformation of the anti-
gen is different [11]. We also noted that no immunized
patients exhibited strong antibody responses after the limited
course of subcutaneous injections (that is, titres were <1/40
to 1/80 only), and so the results shown for 1/40 serum dilu-
tions are specific and represent essentially maximum reactivity.
It is difficult to conclude firmly that antibody and/or T cell
responses led to nonrecurrence of tumour, but it is possible
that the persistent presence of antibody would bind to small
metastatic deposits, leading to their eradication, whereas with
large deposits there is the difficulty of penetration of the anti-
body into the tumour cell mass; similar comments apply to T
cells. We note a study [47] in which it was demonstrated that
the occurrence of MUC1 antibodies without immunization in
early breast cancer patients (stages I and II) were associated
with significant benefit in terms of disease-specific survival.
Patients immunized in our trial and who had developed IgM
and IgG antibodies appeared to have benefit, with significantly
delayed recurrence. We await the results of a larger study (in
excess of 360 patients, which is in progress (EOF ethics
approval, 30 December 2004; no. 64055)) before we draw
firm conclusions on the role of anti-MUC1 immunity and lack
of recurrence.
Finally, although antibody production and cellular immunity
occurred only in the immunized group, there was no control
group with oxidized mannan only; it is theoretically possible
that the mannan, by cross-linking mannose receptors on mac-
rophages and dendritic cells, could lead to their activation. An
endogenous immune response could eradicate tumour depos-
its or activate macrophages, which could eradicate tumour
cells because macrophages are known to be cytocidal to
tumour cells in the absence of any immune response. How-
ever, in many experimental studies mannan mixed with MUC1
FP failed to induce the necessary immune responses and
tumour protection to have any impact on tumour cell growth in
mice [19,20]. Therefore, this mechanism is unlikely to account
for the results presented here.
Conclusion
This study provides important justification for studies of immu-
notherapeutic studies in patients with early/minimal/no evi-
dence of disease. It also suggests that M-FP confers some
benefit. A larger trial is now in progress (multicentre trial to
include >360 patients), which will yield further data.
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